^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GPC3 expression

    i
    Entrez ID:
    2719
    Related biomarkers:
    Expression
    Apply
    GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) (NCT05003895)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    12/08/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    GPC3
    |
    GPC3 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (NCT05450562)
    Phase 1/2
    Sanofi
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    09/20/2022
    Primary completion :
    12/12/2030
    Completion :
    12/12/2030
    ALK • GPC3
    |
    GPC3 expression • GPC3 positive
    |
    Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200
    T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA3) (NCT04864054)
    Phase 2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    05/06/2024
    Initiation :
    03/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (NCT05155189)
    Phase 1
    Zhejiang University
    Recruiting
    Last update posted :
    04/04/2024
    Initiation :
    12/09/2021
    Primary completion :
    05/01/2026
    Completion :
    05/01/2041
    GPC3
    |
    GPC3 expression
    |
    Lenvima (lenvatinib) • AZD7003
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC (NCT05652920)
    Phase 1/2
    OriCell Therapeutics Co., Ltd.
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    12/15/2022
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    GPC3
    |
    GPC3 expression
    |
    Ori-C101
    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1) (NCT05120271)
    Phase 1/2
    Sotio Biotech Inc.
    Recruiting
    Last update posted :
    01/11/2024
    Initiation :
    05/18/2022
    Primary completion :
    04/01/2026
    Completion :
    12/01/2041
    EGFR • ALK • BRCA • GPC3
    |
    EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression
    |
    cyclophosphamide • BOXR1030
    A Study of TAK-102 in Adult With Previously-Treated Solid Tumors (NCT04405778)
    Phase 1
    Takeda
    Active, not recruiting
    Last update posted :
    12/27/2023
    Initiation :
    07/10/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression
    |
    NIB102
    A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (NCT04928677)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/28/2023
    Initiation :
    06/09/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    GPC3
    |
    GPC3 expression
    |
    codrituzumab (RG7686)
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (ZZCART-003) (NCT03198546)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/28/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2025
    Completion :
    08/01/2029
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    TGFβ targeting CAR-T cells
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors (NCT05123209)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Recruiting
    Last update posted :
    11/17/2021
    Initiation :
    08/24/2021
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • PD-1 • GPC3
    |
    GPC3 expression
    |
    IM83
    Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (NCT04951141)
    Phase 1
    Beijing Immunochina Medical Science & Technolog...
    Recruiting
    Last update posted :
    07/05/2021
    Initiation :
    01/01/2019
    Primary completion :
    09/30/2023
    Completion :
    12/21/2023
    GPC3
    |
    GPC3 expression
    |
    IM83
    CAR-T Cell Immunotherapy for HCC Targeting GPC3 (NCT02723942)
    Phase 1/2
    Fuda Cancer Hospital, Guangzhou
    Withdrawn
    Last update posted :
    07/16/2020
    Initiation :
    06/01/2015
    Primary completion :
    08/15/2016
    Completion :
    08/15/2016
    GPC3
    |
    GPC3 expression
    A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (NCT01507168)
    Phase 2
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/03/2020
    Initiation :
    02/02/2012
    Primary completion :
    08/20/2015
    Completion :
    08/20/2015
    GPC3
    |
    GPC3 expression
    |
    codrituzumab (RG7686)
    CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma (NCT03146234)
    Phase N/A
    RenJi Hospital
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    03/17/2017
    Primary completion :
    10/18/2018
    Completion :
    10/18/2018
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • CT0180
    Anti-GPC3 CAR T for Treating Patients With Advanced HCC (NCT02395250)
    Phase 1
    RenJi Hospital
    Completed
    Last update posted :
    08/28/2019
    Initiation :
    03/01/2015
    Primary completion :
    06/01/2016
    Completion :
    11/01/2018
    GPC3
    |
    GPC3 expression • GPC3 positive
    A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) (NCT03130712)
    Phase 1/2
    Shanghai GeneChem Co., Ltd.
    Unknown status
    Last update posted :
    04/26/2017
    Initiation :
    04/01/2017
    Primary completion :
    03/31/2018
    Completion :
    03/31/2018
    IL6 • IL2RA • GPC3 • IL10
    |
    GPC3 expression
    A Study of GPC3 Redirected Autologous T Cells for Advanced HCC (GPC3-CART) (NCT02715362)
    Phase 1/2
    Shanghai GeneChem Co., Ltd.
    Unknown status
    Last update posted :
    03/22/2016
    Initiation :
    03/01/2016
    Primary completion :
    07/01/2018
    Completion :
    03/01/2019
    IL6 • IL2RA • GPC3 • IL10
    |
    GPC3 expression
    |
    cyclophosphamide • TAI-GPC3-CART cells